Effect of SGLT2 Inhibitors on Anemic CKD Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: SGLT2 inhibitor.
- Who it may be relevant to
- Registry conditions: Anemia in CKD Patients. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of SGLT2 Inhibitors On Anemia in Patients With Chronic Kidney Disease (CKD)
Overview
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD
Interventions
- Drug SGLT2 inhibitor
prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1\_4
Primary outcome measures
- hemoglobin level [Time frame: 12 weeks]
- change in hemoglobin level [Time frame: 12 weeks]
Eligibility criteria
Inclusion criteria
- age more than 18 years
- CKD stage 1\_4
- baseline hemoglobin 8.5 to 12.9 g/dl
- stable anemia regimen for more than 8 weeks
Exclusion criteria
- dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Egypt · 1 center
- Sohag University Hospital — Sohag
Identifiers
NCT: NCT07334145 · soh_med__25_12_6MS